APU
CASC

Alpine Partners USVI’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Alpine Partners USVI’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-4,889
Closed -$46K – 163
2013
Q2 		$46K Buy
+4,889
New +$62.8K 0.01% 174

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alpine Partners USVI's CASC Position: Q3 2013 in Review

Alpine Partners USVI sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2013, closing a stake of 4,889 shares — an estimated $46K sold.

Alpine Partners USVI first reported a position in CASC in Q2 2013 and held it in 1 quarter. The position peaked at $46K in Q2 2013. 63 funds tracked by Wall St. Rank hold CASC as of Q3 2013.

  • Alpine Partners USVI reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 4,889 Cascadian Therapeutics, Inc. shares in Q3 2013, an estimated $46K.
  • Alpine Partners USVI first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 1 quarter.
  • Alpine Partners USVI's Cascadian Therapeutics, Inc. position peaked at $46K in Q2 2013.
  • 63 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2013.

Based on Alpine Partners USVI's 13F filing for Q3 2013, filed 14 Nov 2013.